Combined HIV antiretroviral therapy (cART) has been effective except if drug resistance
emerges. As cART has been rolled out in low-income countries, drug resistance has …

Background Long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) is
recommended by WHO as an additional option for HIV prevention in sub-Saharan Africa, but …

Introduction Combination antiretroviral therapy (cART) has dramatically reduced morbidity
and mortality of HIV-1-infected patients. Integrase strand transfer inhibitors (INSTIs) play an …

Cabotegravir (CAB) is an integrase strand transfer inhibitor (INSTI) formulated as a long-
acting injectable drug approved for pre-exposure prophylaxis and use with a long acting …

ABSTRACT HIV-1 integrase (IN) has a noncatalytic function in virion maturation through its
binding to the viral RNA genome (gRNA). Class II IN substitutions inhibit IN-gRNA binding …

Allosteric integrase (IN) inhibitors (ALLINIs), which are promising preclinical compounds that
engage the lens epithelium-derived growth factor (LEDGF)/p75 binding site on IN, can …

Previously, we reported that an HIV-1 variant containing Met-to-Ile change at codon 50 and
Val-to-Ile mutation at codon 151 of integrase (IN), HIV (IN: M50I/V151I), was an impaired …

Islatravir (ISL) is a novel antiretroviral that inhibits HIV-1 reverse transcriptase translocation.
The M184V mutation, known to reduce ISL's viral susceptibility in vitro, could arise from …

We have recently reported that a recombinant HIV-1NL4. 3 containing Met-to-Ile change at
codon 50 of integrase (IN)(IN: M50I) exhibits suppression of the virus release below 0.5% of …

Background In prior studies, HIV-1 BF recombinants with subtype F integrases failed to
develop resistance to raltegravir through the Q148H mutational pathway. We aimed to …